Jefferies Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-44,000
| Closed | -$3.19M | – | 1668 |
|
|
2022
Q2 | $3.39M | Buy |
44,000
+6,750
| +18% | +$514K | 0.03% | 454 |
|
|
2022
Q1 | $2.72M | Buy |
37,250
+750
| +2% | +$50.4K | 0.02% | 585 |
|
|
2021
Q4 | $2.28M | Sell |
36,500
-156,350
| -81% | -$9.17M | 0.01% | 750 |
|
|
2021
Q3 | $11.4M | Buy |
192,850
+178,436
| +1,238% | +$11.8M | 0.08% | 224 |
|
|
2021
Q2 | $963K | Buy |
14,414
+10,338
| +254% | +$674K | 0.01% | 1000 |
|
|
2021
Q1 | $257K | Sell |
4,076
-9,727
| -70% | -$605K | ﹤0.01% | 1283 |
|
|
2020
Q4 | $856K | Buy |
13,803
+13,075
| +1,796% | +$804K | 0.01% | 989 |
|
|
2020
Q3 | $44K | Sell |
728
-407
| -36% | -$24.5K | ﹤0.01% | 1291 |
|
|
2020
Q2 | $67 | Sell |
1,135
-102,239
| -99% | -$6.12M | ﹤0.01% | 1143 |
|
|
2020
Q1 | $5.76M | Sell |
103,374
-219,669
| -68% | -$13.4M | 0.06% | 274 |
|
|
2019
Q4 | $20.7M | Buy |
323,043
+192,382
| +147% | +$11M | 0.16% | 109 |
|
|
2019
Q3 | $6.63M | Sell |
130,661
-167,909
| -56% | -$7.89M | 0.05% | 376 |
|
|
2019
Q2 | $13.5M | Sell |
298,570
-71,649
| -19% | -$3.34M | 0.1% | 160 |
|
|
2019
Q1 | $17.7M | Buy |
370,219
+340,745
| +1,156% | +$17M | 0.15% | 95 |
|
|
2018
Q4 | $1.53M | Buy |
29,474
+197
| +0.7% | +$10.6K | 0.01% | 958 |
|
|
2018
Q3 | $1.82M | Buy |
29,277
+27,038
| +1,208% | +$1.6M | 0.01% | 1032 |
|
|
2018
Q2 | $124K | Sell |
2,239
-38,677
| -95% | -$2.09M | ﹤0.01% | 2105 |
|
|
2018
Q1 | $2.59M | Sell |
40,916
-183,771
| -82% | -$11.8M | 0.01% | 737 |
|
|
2017
Q4 | $13.8M | Buy |
224,687
+27,386
| +14% | +$1.71M | 0.06% | 213 |
|
|
2017
Q3 | $12.6M | Buy |
197,301
+109,342
| +124% | +$6.38M | 0.08% | 217 |
|
|
2017
Q2 | $4.9M | Sell |
87,959
-55,391
| -39% | -$3.01M | 0.03% | 538 |
|
|
2017
Q1 | $7.79M | Sell |
143,350
-341,965
| -70% | -$18.8M | 0.06% | 339 |
|
|
2016
Q4 | $28.4M | Buy |
485,315
+38,541
| +9% | +$2.11M | 0.16% | 97 |
|
|
2016
Q3 | $24.1M | Buy |
446,774
+398,206
| +820% | +$25.6M | 0.12% | 129 |
|
|
2016
Q2 | $3.57M | Sell |
48,568
-70,077
| -59% | -$4.95M | 0.02% | 633 |
|
|
2016
Q1 | $7.58M | Buy |
118,645
+97,161
| +452% | +$6.13M | 0.04% | 334 |
|
|
2015
Q4 | $1.48M | Sell |
21,484
-1,501
| -7% | -$99.2K | 0.01% | 1000 |
|
|
2015
Q3 | $1.36M | Buy |
22,985
+21,966
| +2,156% | +$1.39M | 0.01% | 1075 |
|
|
2015
Q2 | $68K | Sell |
1,019
-268,554
| -100% | -$17.7M | ﹤0.01% | 2334 |
|
|
2015
Q1 | $17.4M | Sell |
269,573
-31,187
| -10% | -$1.95M | 0.1% | 135 |
|
|
2014
Q4 | $17.8M | Sell |
300,760
-5,671
| -2% | -$320K | 0.1% | 166 |
|
|
2014
Q3 | $15.7M | Buy |
306,431
+99,628
| +48% | +$4.98M | 0.11% | 167 |
|
|
2014
Q2 | $10M | Sell |
206,803
-57,364
| -22% | -$2.83M | 0.08% | 205 |
|
|
2014
Q1 | $13.7M | Buy |
264,167
+206,612
| +359% | +$11M | 0.13% | 135 |
|
|
2013
Q4 | $3.06M | Sell |
57,555
-44,024
| -43% | -$2.24M | 0.02% | 439 |
|
|
2013
Q3 | $4.7M | Buy |
101,579
+46,926
| +86% | +$2.06M | 0.05% | 344 |
|
|
2013
Q2 | $2.44M | Buy |
+54,653
| New | +$2.37M | 0.03% | 437 |
|
Other funds holding BMY
Jefferies Group's BMY Position: Q3 2022 in Review
Jefferies Group sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 44,000 shares — an estimated $3.19M sold.
Jefferies Group first reported a position in BMY in Q2 2013 and held it in 37 quarters. The position peaked at $28.4M in Q4 2016. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- Jefferies Group reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
- Jefferies Group sold 44,000 Bristol-Myers Squibb shares in Q3 2022, an estimated $3.19M.
- Jefferies Group first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 37 quarters.
- Jefferies Group's Bristol-Myers Squibb position peaked at $28.4M in Q4 2016.
- 2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.